Physician profile
Saedra E Patella
NPI 1881978245
$5,482.50
in general payments reported to CMS, 2019-2025
20 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $549 · 2022: $605 · 2023: $1,482 · 2024: $814 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,328.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,714.09 | 2021-2025 | Aveir, Cardiomems, Jot Dx |
| Cvrx, INC. | $842.73 | 2024-2025 | Barostim Neo System |
| Boston Scientific Corporation | $613.01 | 2021-2025 | Watchman Flx, Watchman Access System |
| Medtronic, INC. | $476.62 | 2021-2025 | Cobalt Dr Mri Surescan, Micra, Linq II |
| Biotronik INC. | $380.18 | 2021-2025 | Edora 8 Dr-T, Acticor 7 Vr-T Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $333.24 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $183.00 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $177.23 | 2023-2024 | Assure Wcd |
| Atricure, INC. | $169.30 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Edwards Lifesciences Corporation | $157.50 | 2022 | |
| Impulse Dynamics (USA) INC. | $129.68 | 2024-2025 | Optimizer |
| Alnylam Pharmaceuticals INC. | $60.64 | 2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.91 | 2022-2024 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $50.61 | 2024 | Arcalyst |
| Altathera Pharmaceuticals LLC | $38.58 | 2023 | Sotalol Hydrochloride |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.62 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $20.76 | 2023 | Farxiga |
| Cardiva Medical, INC. | $20.68 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Convatec INC. | $14.67 | 2022 | |
| Novo Nordisk INC | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saedra Patella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.